159 related articles for article (PubMed ID: 32727899)
1. An ErbB2 splice variant lacking exon 16 drives lung carcinoma.
Smith HW; Yang L; Ling C; Walsh A; Martinez VD; Boucher J; Zuo D; Sokol ES; Pavlick DC; Frampton GM; Chmielecki J; Jones LM; Roux PP; Lockwood WW; Muller WJ
Proc Natl Acad Sci U S A; 2020 Aug; 117(33):20139-20148. PubMed ID: 32727899
[TBL] [Abstract][Full Text] [Related]
2. The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment.
Turpin J; Ling C; Crosby EJ; Hartman ZC; Simond AM; Chodosh LA; Rennhack JP; Andrechek ER; Ozcelik J; Hallett M; Mills GB; Cardiff RD; Gray JW; Griffith OL; Muller WJ
Oncogene; 2016 Nov; 35(47):6053-6064. PubMed ID: 27157621
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of
Shi L; Xu C; Ma Y; Ou Q; Wu X; Lu S; Shao Y; Guo R; Kong J
ESMO Open; 2020 Nov; 5(6):e000985. PubMed ID: 33214226
[TBL] [Abstract][Full Text] [Related]
4. Investigation of the prevalence and clinical implications of
Shang Y; Mo J; Huo R; Li X; Fang G; Wei Z; Gu G; Zhu X; Zhang C; Liu C; Yan D
Front Oncol; 2022; 12():1064598. PubMed ID: 36686783
[TBL] [Abstract][Full Text] [Related]
5. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.
Saigi M; McLeer-Florin A; Pros E; Nadal E; Brambilla E; Sanchez-Cespedes M
Clin Transl Oncol; 2018 Jul; 20(7):881-888. PubMed ID: 29139039
[TBL] [Abstract][Full Text] [Related]
6. The human splice variant Δ16HER2 induces rapid tumor onset in a reporter transgenic mouse.
Marchini C; Gabrielli F; Iezzi M; Zenobi S; Montani M; Pietrella L; Kalogris C; Rossini A; Ciravolo V; Castagnoli L; Tagliabue E; Pupa SM; Musiani P; Monaci P; Menard S; Amici A
PLoS One; 2011 Apr; 6(4):e18727. PubMed ID: 21559085
[TBL] [Abstract][Full Text] [Related]
7. EGFR and erbB2 mutation status in Japanese lung cancer patients.
Sasaki H; Shimizu S; Endo K; Takada M; Kawahara M; Tanaka H; Matsumura A; Iuchi K; Haneda H; Suzuki E; Kobayashi Y; Yano M; Fujii Y
Int J Cancer; 2006 Jan; 118(1):180-4. PubMed ID: 16003726
[TBL] [Abstract][Full Text] [Related]
8. ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Wang YP; Jo KH; Moon SW; Song SY; Lee JY; Yoo NJ; Lee SH
Cancer Lett; 2006 Jun; 237(1):89-94. PubMed ID: 16029927
[TBL] [Abstract][Full Text] [Related]
9. Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.
Costa DB; Jorge SE; Moran JP; Freed JA; Zerillo JA; Huberman MS; Kobayashi SS
J Thorac Oncol; 2016 Jun; 11(6):918-23. PubMed ID: 26964772
[TBL] [Abstract][Full Text] [Related]
10. Splice variants of the extracellular region of RON receptor tyrosine kinase in lung cancer cell lines identified by PCR and sequencing.
Krishnaswamy S; Mohammed AK; Tripathi G; Alokail MS; Al-Daghri NM
BMC Cancer; 2017 Nov; 17(1):738. PubMed ID: 29121914
[TBL] [Abstract][Full Text] [Related]
11. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
[TBL] [Abstract][Full Text] [Related]
12. Autocrine activation of ErbB2/ErbB3 receptor complex by NRG-1 in non-small cell lung cancer cell lines.
Gollamudi M; Nethery D; Liu J; Kern JA
Lung Cancer; 2004 Feb; 43(2):135-43. PubMed ID: 14739033
[TBL] [Abstract][Full Text] [Related]
13. Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
Suzawa K; Offin M; Lu D; Kurzatkowski C; Vojnic M; Smith RS; Sabari JK; Tai H; Mattar M; Khodos I; de Stanchina E; Rudin CM; Kris MG; Arcila ME; Lockwood WW; Drilon A; Ladanyi M; Somwar R
Clin Cancer Res; 2019 Feb; 25(4):1248-1260. PubMed ID: 30352902
[TBL] [Abstract][Full Text] [Related]
14. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
15. Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.
Peng M; Ball-Kell SM; Tyner AL
Cell Death Dis; 2015 Aug; 6(8):e1848. PubMed ID: 26247733
[TBL] [Abstract][Full Text] [Related]
16. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.
Shimamura T; Ji H; Minami Y; Thomas RK; Lowell AM; Shah K; Greulich H; Glatt KA; Meyerson M; Shapiro GI; Wong KK
Cancer Res; 2006 Jul; 66(13):6487-91. PubMed ID: 16818618
[TBL] [Abstract][Full Text] [Related]
17. ERBB2 Regulates MED24 during Cancer Progression in Mice with
Liu J; Wang T; Willson CJ; Janardhan KS; Wu SP; Li JL; DeMayo FJ
Cells; 2019 Jun; 8(6):. PubMed ID: 31248101
[TBL] [Abstract][Full Text] [Related]
18. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.
Minami Y; Shimamura T; Shah K; LaFramboise T; Glatt KA; Liniker E; Borgman CL; Haringsma HJ; Feng W; Weir BA; Lowell AM; Lee JC; Wolf J; Shapiro GI; Wong KK; Meyerson M; Thomas RK
Oncogene; 2007 Jul; 26(34):5023-7. PubMed ID: 17311002
[TBL] [Abstract][Full Text] [Related]
19. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
Onozato R; Kosaka T; Kuwano H; Sekido Y; Yatabe Y; Mitsudomi T
J Thorac Oncol; 2009 Jan; 4(1):5-11. PubMed ID: 19096300
[TBL] [Abstract][Full Text] [Related]
20. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
